Pasithea activates UAB site for Phase 1/1b PAS-004 NF1 trial; platinum sponsor of symposium

Pasithea Therapeutics Corp.

New U.S. clinical site at University of Alabama at Birmingham activated for ongoing Phase 1/1b PAS-004 trial in adult NF1 patients; enrollment starts immediately.
PAS-004 is a next-generation macrocyclic oral MEK inhibitor being studied for symptomatic, inoperable plexiform neurofibromas.
Pasithea named Platinum Sponsor of the 2025 NF Caregivers Symposium at UAB on November 8, 2025.
CEO Tiago Reis Marques highlighted UAB's deep NF1 expertise and commitment to advancing care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.